Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-arm, Non-randomized Controlled, Open-label Clinical Study of Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line Esophageal Squamous Cell Carcinoma.

NCT06464614 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Henan University of Science and Technology as lead sponsor.

NCT NCT06464614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06464614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-arm, Non-randomized Controlled, Open-label Clinical Study of Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line Esophageal Squamous Cell Carcinoma.
Lead sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Phase
Phase 2
Overall status
Unknown status
Start date
July 15, 2024
Completion date
August 1, 2026
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer